

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/M0F8DAF3CF4EN.html>

Date: September 2018

Pages: 59

Price: US\$ 3,500.00 (Single User License)

ID: M0F8DAF3CF4EN

Abstracts

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Melanocyte Stimulating Hormone Receptor Pipeline Review, H2 2018'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 10 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotrophic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor Pipeline Review, H2 2018' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 6 respectively. Report covers products from therapy areas Dermatology, Central Nervous System, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Genetic Disorders, Genito Urinary System And Sex Hormones and Oncology which include indications Vitiligo, Amyotrophic Lateral Sclerosis, Gouty Arthritis (Gout), Infantile Spasm (West Syndrome), Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease, Metastatic Melanoma, Multiple Sclerosis, Ocular Inflammation, Peritonitis, Porphyria (Erythropoietic Protoporphyrin), Psoriatic Arthritis, Ulcerative Colitis and Uveitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Ltd

Mallinckrodt Plc

Palatin Technologies Inc

SolaranRx Inc

SynAct Pharma AB

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles

afamelanotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-1189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8331 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-1177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones

Featured News & Press Releases

Jun 28, 2018: Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

Jun 25, 2018: Clinuvel Completes Scenesse FDA Filing

Jun 18, 2018: Mallinckrodt Reports Interim Findings Of H.P. Acthar Gel (Repository Corticotropin Injection) Studies

Jun 16, 2018: Mallinckrodt Presents Preliminary Interim Findings of Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar Gel (Repository Corticotropin Injection)

Jun 01, 2018: Mallinckrodt Presents Interim Findings of Multiple Sclerosis Relapse Registry for H.P. Acthar Gel

May 23, 2018: Nice Maintains Its Position Not To Recommend Scenesse For Reimbursement

May 14, 2018: CLINUVEL Provides Regulatory Update

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on its Drug Candidate PL-8177 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

May 09, 2018: Palatin Technologies Presents Positive Preclinical Data on PL-8331 at TIDES: Oligonucleotide and Peptide Therapeutics 2018 Meeting in Boston, Massachusetts

May 07, 2018: Mallinckrodt Provides Facts on H.P. Acthar Gel

Apr 03, 2018: Palatin Technologies presents preclinical oral formulation data on PL-8177, an investigational melanocortin receptor 1 Agonist for inflammatory bowel disease

Mar 28, 2018: MNK H.P. Acthar Gel CHART Trial Results Alert

Mar 19, 2018: Clinuvel Holds European Erythropoietic Protoporphyrin (EPP) Expert Meeting

Feb 05, 2018: Palatin Technologies, Inc. Initiates Subject Dosing in First-in-Human Clinical Study of PL-8177, an Investigational Melanocortin Receptor 1 Agonist

Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Clinuvel Pharmaceuticals Ltd, H2 2018

Pipeline by Mallinckrodt Plc, H2 2018

Pipeline by Palatin Technologies Inc, H2 2018

Pipeline by SolaranRx Inc, H2 2018

Pipeline by SynAct Pharma AB, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd.1), H2 2018

Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Clinuvel Pharmaceuticals Ltd

Mallinckrodt Plc

Palatin Technologies Inc

SolaranRx Inc

SynAct Pharma AB

I would like to order

Product name: Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
- Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/M0F8DAF3CF4EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M0F8DAF3CF4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

